View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Forian Inc. Announces Fourth Quarter and Full Year 2023 Financial Resu...

Forian Inc. Announces Fourth Quarter and Full Year 2023 Financial Results Full Year 2023 Revenue Grew 25% Full Year 2023 Adjusted EBITDA of $2.3MM NEWTOWN, PA, March 28, 2024 (GLOBE NEWSWIRE) -- via -- Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter and year ended December 31, 2023. “Forian finished the year by executing against our quarterly plan and closed what was a transformational year,” stated Max Wygod, Chairman and Chief Exe...

 PRESS RELEASE

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports F...

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Fourth-Quarter and Full-Year Fiscal 2023 Results; Posts 11% Annual Sales Growth; Announces 3% Increase in Quarterly Dividend Full-year sales increased 11% to $1.57 billionFiscal 2023 GAAP EPS of $3.82 impacted by noncash impairment charges of $5.32 per share. Adjusted EPS of $10.15, within guidance rangeInitiates fiscal 2024 guidance of revenues of $1.630 billion to $1.670 billion, GAAP EPS of $8.80 to $9.20 and adjusted EPS of $9.30 to $9.70 ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:...

 PRESS RELEASE

Revolution Medicines to Deliver Multiple Presentations at the Upcoming...

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California. Details of the planned presentation...

 PRESS RELEASE

Fortress Biotech Reports 2023 Financial Results and Recent Corporate H...

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term va...

 PRESS RELEASE

TPI Composites, Inc. Publishes its Annual Sustainability Report Reaffi...

TPI Composites, Inc. Publishes its Annual Sustainability Report Reaffirming Its Commitments to a Zero-Harm Culture and Carbon Neutrality SCOTTSDALE, Ariz., March 28, 2024 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (Nasdaq: TPIC), today published its 2023 sustainability report highlighting its progress on organizational and global impacts related to sustainability. Bill Siwek, President, and CEO noted, “Providing the means necessary for the world to embrace renewable energy and reduce reliance on fossil fuels is the foundation of our company and we are dedicated to doing so responsibly. W...

 PRESS RELEASE

ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer

ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer VELDHOVEN, the Netherlands, March 28, 2024 – ASML Holding NV (ASML) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC to purchase up to 250,000 (two hundred and fifty thousand) of ASML’s ordinary shares, nominal value €0.09 per share, representing significantly less than 0.1% of ASML’s ordinary shares, at an offer price of $1,075 net per share. ASML is not associated in any way with Tutanota or i...

 PRESS RELEASE

Cartesian Therapeutics Announces Approval of Conversion of Series A Co...

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split Proposals approved at Company’s special meeting of stockholders held March 27, 2024 GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced results from a special meeting of stockholders held March 27, 2024. During the meeting, Cartesian stockholders approved the issuance of shares of co...

 PRESS RELEASE

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year...

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results -- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023. Fourth Quarter and Recent Business Updates Secured Healthcare Common Procedure Coding System (“HCPCS”) Level II codes for the Portab...

 PRESS RELEASE

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Result...

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bi...

 PRESS RELEASE

Leading Proxy Advisory Firms Recommend ContextLogic Stockholders Vote ...

Leading Proxy Advisory Firms Recommend ContextLogic Stockholders Vote “FOR” Pending Transaction with Qoo10 ISS, Glass Lewis and Egan-Jones Endorse Proposed Transaction Stockholders are Encouraged to Vote FOR the Value-Maximizing Transaction Before the Electronic Proxy Voting Deadline of 11:59 P.M. Eastern Time on Thursday, April 11, 2024 SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH) (“ContextLogic” or the “Company”) today announced that proxy advisory firms Institutional Shareholder Services (“ISS”), Glass Lewis and Egan-Jones have all r...

 PRESS RELEASE

Ardelyx, Inc. Reports Employment Inducement Grants

Ardelyx, Inc. Reports Employment Inducement Grants WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on March 25, 2024, the compensation committee of the company’s board of directors granted a non-qualified stock option award to purchase 205,000 shares of its common stock and a restricted stock unit award for 160,000 shares in connection with the commencement of employme...

 PRESS RELEASE

Acuity Brands Declares Quarterly Dividend

Acuity Brands Declares Quarterly Dividend Atlanta, March 28, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of (NYSE: AYI; "Company") today declared a quarterly dividend of 15 cents per share. The dividend is payable on May 1, 2024, to shareholders of record on April 17, 2024. About Acuity Brands Acuity Brands, Inc. (NYSE: AYI) is a market-leading industrial technology company. We use technology to solve problems in spaces, light, and more things to come. Through our two business segments, Acuity Brands Lighting and Lighting Controls (ABL) and the Intelligent Spaces Group (ISG), we de...

 PRESS RELEASE

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial...

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses Declined 27% Due to Success of Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company special...

 PRESS RELEASE

CGRA Announces Completion and Publication of 2023 Annual Disclosure

CGRA Announces Completion and Publication of 2023 Annual Disclosure NEW YORK, NY, March 28, 2024 (GLOBE NEWSWIRE) -- via -- CGrowth Capital Inc. (OTC: CGRA) is a public holding company for alternative and undervalued assets. The company is sector and industry agnostic and currently consists of two divisions including Mining and Sports Technology. The company is focused on investing in growth-oriented opportunities where the company’s capital, expertise, and capabilities can help create significant added value for shareholders. CGRA is pleased to announce the completion and publicati...

 PRESS RELEASE

Candel Therapeutics Announces Oral Presentation During the 5th Gliobla...

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial.The serial procedures were well tolerated without observed dose-limiting toxicity.A second cohort is being planned for enrollment in the ongoing phase 1b clinical trial of CAN-3110. NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CA...

 PRESS RELEASE

Femasys Announces Financial Results for Year Ended December 31, 2023 a...

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corp...

 PRESS RELEASE

Sharecare announces fourth quarter and full year 2023 financial result...

Sharecare announces fourth quarter and full year 2023 financial results and operational highlights ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced financial results for the quarter and year ended December 31, 2023. "In my first three months as CEO, I have been increasingly impressed by Sharecare's ability to innovate, and I believe that the breadth and depth of assets that the company has assembled over the years gives us everything we need to be successful,” said Bren...

 PRESS RELEASE

Absci to Participate in the 23rd Annual Needham Virtual Healthcare Con...

Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference VANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Absci management is scheduled to present on Monday, April 8th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: . About Absci is a data-f...

 PRESS RELEASE

Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests

Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today it completed an acquisition of mineral interests totaling approximately 1,485 net royalty acres located in two counties in Colorado. The transaction was structured as a non-taxable contribution and exchange. The contributing entities conveyed their interests to the Partnership in exchange for 505,369 common units representing limited partnership interests in Dorchester Minerals, L.P. Dorchester Mineral...

 PRESS RELEASE

Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with La...

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Grappler® R3INFORCE™ Extraosseous Repair System designed to restore stability to the anterior and posterior ligaments surrounding the ankle during fibula fracture repairs and high ankle sprains. This press release features multimedia. View the full release here: Figure 1: Anterior inferior tibiofibular ligament (“AITFL”) Repair Showing the Grappler® R3INFORCE™ Dynamic Anchor (left) and Grappler® Knotless Anchor (center). Complete Extraosseous Repair with Grappler® R3INFORCE™ System shown...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch